Kyprolis carfilzomib: Phase II data

Researchers at the University of Torino reported data from an open-label, European Phase II trial in 58 patients with newly diagnosed MM showing that IV Kyprolis plus cyclophosphamide and dexamethasone led a 2-year PFS rate of 76% and a 2-year OS

Read the full 410 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE